Publications

ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial

Manca P, Paoli M, Galardi F, Morano F, Di Donato S, Biganzoli L, Malorni L, Nardone A, et al.

Clin Cancer Res

Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer

Nasca V, Ambrosini M, Taieb J, Cohen R, Lonardi S, Boursi B, Margalit O, Salvatore L, et al.

Oncologist

First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer

Nasca V, Tinè G, Taieb J, Lonardi S, Boursi B, Margalit O, Salvatore L, Cohen R, et al.

Oncologist

Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, Nichetti F, Ghelardi F, et al.

Clin Cancer Res

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer

Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, et al.

J Immunother Cancer

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade

Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner SJ, Maron SB, Cerantola R, et al.

J Immunother Cancer